期刊文献+

先天性心脏病并肺动脉高压患儿血浆尾加压素Ⅱ与血管内皮生长因子水平的变化 被引量:3

Changes of Plasma Urotensin Ⅱ and Vascular Endothelial Growth Factor in Children with Pulmonary Hypertension Associated with Congenital Heart Disease
原文传递
导出
摘要 目的通过检测左向右分流型先天性心脏病(CHD)并肺动脉高压(PH)患儿血浆尾加压素Ⅱ(UⅡ)与血管内皮生长因子(VEGF)的水平,探讨其在左向右分流型CHD并PH中的临床意义。方法选择2008年1月-2009年1月本院心儿科收治的63例左向右分流型CHD患儿(男30例,女33例),均在右心导管检查中直接测定其肺动脉压力,按肺动脉平均压(mPAP)水平分为无PH组(mPAP≤25mmHg,1mmHg=0.133kPa)21例、轻中度PH组(25mmHg<mPAP≤45mmHg)20例及重度PH组(mPAP>45mmHg)22例。取患儿肺动脉血,采用酶联免疫吸附法(ELISA)测定其肺动脉血浆UⅡ及VEGF水平,分析二者与mPAP的关系。结果 1.无PH组、轻中度PH组及重度PH组肺动脉血浆UⅡ水平比较差异无统计学意义(P>0.05)。肺动脉血浆UⅡ水平与mPAP无相关性(r=-0.003,P>0.05)。2.轻中度及重度PH组与无PH组肺动脉血浆VEGF水平比较差异均有统计学意义(Pa<0.01),轻中度PH组与重度PH组肺动脉血浆VEGF水平比较差异亦有统计学意义(P<0.05);肺动脉血浆VEGF水平与mPAP呈正相关(r=0.761,P<0.01)。结论 1.血浆UⅡ水平随PH程度的加重无明显变化,但不能排除UⅡ在PH形成和血管重建中起重要作用。2.VEGF参与了左向右分流型CHD并PH的病理生理过程,其血浆水平可作为评估左向右分流型CHD患儿PH严重程度的参考指标之一。 Objective To study the clinical significance of plasma urotensin 11 ( U II ) and vascular endothelial growth tactor (VEGF) in children with pulmonary hypertension(PH) associated with left - to - right shunt congenital heart disease (CHD) by detecting the levels of plasma U II and VEGF. Methods From Jan. 2008 to Jan. 2009, a total of 63 children with left - to - right shunt CHD who hospitalized in Beijing Anzhen ttospital were enrolled in the study. Thirty children were male, others were female. Mean pulmonary artery pressure (mPAP) of 63 cases was measured by right heart catheterization. They were divided into 3 groups according to mPAP level as follows:non - PH group (mPAP ≤ 25 mmHg, n = 21 ), mild and moderate PH group(25 mmHg 〈 mPAP ≤45 mmHg, n = 20 ) , severe PH group ( mPAP 〉 45 mmHg, n = 22 ). The blood was drawn from children's pulmonary artery. The levels of plasma U II and VEGF were detected by enzyme - linked immunosorbentassay(ELISA). The relation between the 3 groups and their mPAP were analyzed. Results 1. The level of plasma U II obtained from pulmonary artery was no difference in non -PH group,mild and moderate PH group and severe PH group(P 〉 0.05 ). There was no correlation beween the level of plasma U II arid mPAP( r = -0. 003 ,P 〉0. 05 ). 2. The level of plasma VEGF obtained from puhnonary artery in CHD with PH groups was different significantly from non -PH group( P 〈 0. 01 ). There was also significant difference between mild and moderate PH group and severe PH group( P 〈 0.05 ). There was positive correlation between the level of plasnm VEGF and mPAP(r = 0. 761 ,P 〈 0.01 ). Conclusions 1. The level of plasma U II do not change with the increasing of mPAP,but U 1I might play an important role in the formation of PH and restructure. 2. VEGF might participate in the physiopathologic process in children with PH associated with left - to - right shunt CHD. The level of VEC-F can be used as a reliable indicator to evaluate the severity of PH associated with left - to - right shunt CHD.
出处 《实用儿科临床杂志》 CAS CSCD 北大核心 2010年第13期965-967,共3页 Journal of Applied Clinical Pediatrics
基金 国家"十一.五"科技支撑计划(2006BAI01A07)
关键词 肺动脉高压 心脏病 先天性 尾加压素Ⅱ 血管内皮生长因子 儿童 pulmonary hypertension congenital heart disease urotensin II vascular endothelial growth factor child
  • 相关文献

参考文献16

  • 1Coulouarn Y, Libnnan I, Jegou S, et al. Cloning of cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord [ J ]. Proc Natl Acad Sci U S A, 1998,95 (26) : 15803 - 15808.
  • 2Stirrat A, Gallagher M, Douglas SA,et al. Potent vasodilator responses to human urotensin Ⅱ in human pulmonary and abdominal resistance arteries[J]. Am J Heart Circ Physiol,2001,280( 2 ) :925 -928.
  • 3Ferram N, Davis - Smyth T. The biology of vascular endothelial growth factor[J]. Endocrine Res ,1997 ,18 (1) :4 -25.
  • 4Russell FD. Urotensin Ⅱ in cardiovascular regulation [J]. Vasc Health Risk Manag ,2008,4( 4 ) :775 -785.
  • 5Simpson CM,Penny DJ,Stocker CF,et al. Urotensin Ⅱ is raised in children with congenital heart disease[ J ]. Heart,2006,92 (7) :983 - 984.
  • 6方文珠,陈宏明,黄锦益,罗章伟,黄江河.先天性心脏病合并肺动脉高压患者尾加压素Ⅱ、降钙素基因相关肽和内皮素浓度观察[J].中国体外循环杂志,2008,6(3):159-161. 被引量:3
  • 7杨志祥,王彪,王涛,曹广庆.探讨尾加压素Ⅱ及内皮素在小儿先天性心脏病肺动脉高压中的研究[J].中国实用医药,2008,3(31):7-9. 被引量:2
  • 8范瑾,杜军保,唐朝枢,陈霞,曹军,吴晔.先天性心脏病患儿血浆尾加压素Ⅱ的变化及其临床意义[J].中国实用儿科杂志,2002,17(2):103-103. 被引量:4
  • 9Djordjevic T,BelAiba RS,Bonelio S,et al. Human urotensin Ⅱ is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells [ J ]. Arterioscler Thromb Vasc Biol,2005,25 (3) :519 - 525.
  • 10Tuder RM, Yun JH. Vascular endothelial growth factor of the lung: Friend or foe[ J ]. Curr Opin Pharmacol,2008,8(3 ) :255 - 260.

二级参考文献26

  • 1孙新艳,吴新军,马支媛,张宁,王俊科.体外循环中血浆一氧化氮和内皮素变化的临床观察[J].中国体外循环杂志,2004,2(2):78-80. 被引量:4
  • 2刘志红,孙培吾,曾熙兰,梁虹.先天性心脏病并发肺动脉高压患者血浆前列腺素E_2的变化及意义[J].标记免疫分析与临床,1994,1(4):201-203. 被引量:2
  • 3张泽伟,叶璟,李建华,姜力骏,高展.先天性心脏病肺动脉高压患儿血浆降钙素基因相关肽水平和基因测序的临床意义[J].中华急诊医学杂志,2006,15(3):236-238. 被引量:2
  • 4叶明,贾兵,陈张根,李炘,杨毅,陈莲.内皮素及其受体在家兔体、肺循环中的分布[J].中国临床医学,2006,13(2):214-215. 被引量:2
  • 5[2]Maguire JJ,Kuc RE,Davenport AP.Orphan-receptor ligand human urotensin Ⅱ:receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1[J].Br J pharmacol,2000,131 (3):441 -446.
  • 6[3]Maclean MR,Alexander D,Stirrat A,et al.contractile responses to human urotensin-Ⅱ in rat and human pulmonary arctics:effect of endothelial factors and chronic hypoxia in the rat[J].Br J pharmacd,2000,130(2):201 -204.
  • 7[4]Dounglas SA,Sulpizio AC,Pierey V,et al.Differential vasoconstrictor activity of human urotensin Ⅱ in vascular tissue isolated from the rat,mouse,dog,pig,marmoset and cynomolgus monkey[J].Br J pharmacol,2000,131 (7):1262 -1274.
  • 8[5]Camarda V,Rizzi A,Calo G,et al.Effects of human urotensin Ⅱin isolated vessels of various species;comparison with other vasoactive agents[J].Naunyn Schrniedebergs Arch Pharmacol,2002,365(2):141 -149.
  • 9[1]Mayes MD.Endothelin and endothelin receptor antagonists in systemic rheumatic disease.Arthritis Rheum,2003,48(5):1190-1199.
  • 10[2]Adel G,Yanagisawa M,Langleben D,et al.Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.New Eng J Medic,1993,24(8):7732-7739.

共引文献19

同被引文献26

  • 1Ling-Zhi Liu,En-Ping Wu,Heng-Liang Liu.Relation between K469E gene polymorphism of ICAM-1 and recurrence of ACS and cardiovascular mortality[J].Asian Pacific Journal of Tropical Medicine,2013,6(11):916-920. 被引量:5
  • 2Barst R J,Ertel SI,Beghetti M. Pulmonary arterial hypertension:a comparison between children and adults[J].European Respiratory Journal,2011,(03):665-677.
  • 3Lourenco AP,Fontoura D,Henriques-Coelho T. Current pathophysiological concepts and management of pulmonary hypertension[J].International Journal of Cardiology,2012,(03):350-361.
  • 4Wang Q,Usinger W,Nichols B. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease[J].Fibrogenesis Tissue Repair,2011,(01):4.
  • 5Kono M,Nakamura Y,Suda T. Plasma CCN2 (connective tissue growth factor;CTGF)is a potential biomarker in idiopathic pulmonary fibrosis(IPF)[J].Clinica Chimica Acta,2011,(23-24):2211-2215.
  • 6Price LC,Wort S J,Perros F. Inflammation in pulmonary arterial hypertension[J].Chest,2012,(01):210-221.
  • 7Song JJ,Aswad R,Kanaan RA. Connective tissue growth factor (CTGF) acts as a downstream mediator of TGF-beta1 to induce mesenchymal cell condensation[J].Journal of Cellular Physiology,2007,(02):398-410.doi:10.1002/jcp.20850.
  • 8Rimon E,Chen B,Shanks AL. Hypoxia in human trophoblasts stimulates the expression and secretion of connective tissue growth factor[J].Endocrinology,2008,(06):2952-2958.
  • 9Khankan R,Oliver N,He S. Regulation of fibronectin-EDA through CTGF domain-specific interactions with TGFβ2 and its receptor TGFβRⅡ[J].Investigative Ophthalmology & Visual Science,2011,(08):5068-5078.
  • 10刘斌,王献民,周同甫,华益民,刘瀚曼,魏丽,乔丽娜,王晓琴,赵姗姗,石坤.大鼠肺动脉高压模型结缔组织生长因子的表达及辛伐他汀的调控作用[J].中华儿科杂志,2008,46(5):359-365. 被引量:16

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部